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The myeloproliferative neoplasms (MPN), previously known as myeloproliferative disorders (MPD), are a group of clonal 
hematopoietic stem cell malignancies in which there is an increased proliferation or accumulation of one or more subtypes of 
myeloid cells instead of the destruction of normal haematopoiesis as usually associated with malignancy (de Lacerda, et al 
2014).   
 
Excluding the acute myeloid malignancies, the chronic group is divided into the Philadelphia chromosome (BCR/ABL-1gene) 
positive chronic myeloid leukemia (CML) and negative groups. The latter comprises Polycythaemia Vera (PRV), 
characterized by red cell proliferation, essential thrombocythaemia (ET) with marked thrombocytosis, and primary 
myelofibrosis (PMF), where bone marrow reticulin and collagen deposition is dominant (de Lacerda, et al 2014). The 
suggestion has been made to view PRV, ET, and PMF not as separate diseases, but as different manifestations of the same 
disease, or a combination of both(Spivak and Silver 2008). 
 
In this review of the literature, we will concentrate on the pivotal discovery of the JAK2 V617F mutation on exon 14 of 
chromosome 9p in 2005, in illustration of the revolution it brought about. Its discovery not only provided new insights into 
the molecular basis of the MPD/MPN but also new molecular approaches to their diagnosis(Spivak and Silver 2008). 
  
 
2. The history of the Myeloproliferative Neoplasm 
 
2.1.  Bird’s eye view on guideline development in MPN 
Endeavours at diagnostic criteria for PRV, ET and PMF stem from as early as the 1940’s (Michiels, et al 2015) with 
Dameshek as the first to propose speculative theories involving an unknown factor either stimulating bone marrow 
excessively, or the lack of inhibition of a mysterious factor(Dameshek 1950).  
 
On the basis of CML, following the discovery of the disease-specific Philadelphia chromosome in 1982, the origin of  
ET/PRV/PMF was also expected to be involving constitutively active tyrosine kinase activity, (James, et al 2005b) but until 
2005, this was yet to be proven. 
 
The first diagnostic criteria for MPN was brought out in 1967. Debate persisted furiously between the experts over the 
years, but without consensus groups practiced according to their own convictions. Guideline after guideline was being 
published, because physicians continued to be confounded by the MPN’s.  
 
 
2.2. The Revelation of the JAK2 V617F mutation 
In 2005, the identification of the JAK2 mutation and its significance to change myeloproliferative disorders to 
myeloproliferative neoplasms, was broadcasted to the medical world in no less than four publications by four independent 
research groups across the globe over a period of 2 months.  
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Baxter, et al (2005a), described the single point mutation (Val617Phe) in JAK2, in a population of known MPN patients. 
Short on their heels, followed James, et al (2005a) in their description of JAK2V617F in PRV patients. Levine, et al (2005b) 
and a Swiss group, Kralovics, et al (2005) published within the next month with similar methods and findings.  
 
What the JAK2 mechanism unveiled is the common stem-cell clonal heritage of the MPNs, and that its diverse phenotypes 




2.3. JAK2 V617F mutation molecular mechanism 
The acquired mutation within JAK2 exon 14 was identified on codon 617 of the JAK2 JH2 domain. There, valine (V), is 
replaced by phenylalanine (F). The ensuing JAK2V617F mutation interferes with the auto-inhibitory activity of the JH2 
pseudokinase part, leading to enhanced activity and constitutive activation of the tyrosine kinase function. These mutated 
haematopoietic stem cells become hypersensitive to haematopoietic growth factors resulting in the lineage abnormalities 
characteristic of MPN (Bench, et al 2013, Michiels, et al 2015).  
 
The JAK2 kinase activity is furthermore influenced by both the allele burden and various steps up- or downstream of the 
signalling pathways. (Michiels, et al 2015) 
 
In summary, all of the driver mutations lead to JAK2 activation in MPNs, and the development of cytoses are related to an 




2.4. Brief summary of developments prompted by JAK2 V617F  
In the revised 2008 WHO classification for chronic myeloid neoplasms, the phrase “disease” is replaced by “neoplasm” for 
the first time. With the renewed interest in this group of diseases, terminology for thrombocythaemia and myelofibrosis also 
became standardised, where before there existed several different names for each.  
 
JAK2 is nowadays considered conditio sine qua non for the diagnosis of PV and it simplified diagnosing ET and PMF in at least 
50% of cases(Tefferi 2008).  
 
While not the focus of this review, the improved understanding of disease pathogenesis also resulted in new targeted 
therapies (Stein, et al 2011).  
  
2.5. Other mutations diagnostic in MPN 
The most important mutations other than JAK2V617F include the JAK2 exon 12, MPL exon 10 and the most recently 
identified CALR mutation. The JAK-STAT pathway appears to be activated in all MPN, regardless of founding driver 
mutations. Increasingly, however, the difference is manifested with effects on the clinical course and outcomes(63). Even 
though they are not available in our setting at present, they may become relevant in the future as they are implemented in 
standard diagnostic algorithms.  
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2.5.1. JAK2 V617F exon 12 
In the small group of JAK2 exon 14 negative PV patients, 3% of patients do demonstrate the exon 12 mutation. This finding 
confirms the strong association between the JAK2 mutations and MPN. Patients with this mutation usually present with 
early-stage PV with a good outcome and normal life expectancy according to Michiels (3), but Tefferi holds their outcome to 
be prognostically similar to the exon 14 patients (36). Additional observations by the latter include presentation with 
predominantly erythroid myelopoiesis, subnormal EPO and a younger age at diagnosis. Many of these JAK2V617F exon 14 




MPL was discovered prior to the JAK2V617F mutation, in 2004, based on a case of congenital ET. Henceforth, it was noted 
to exist in ET and MF but rarely in PV (3).  It occurs in around 4% of ET patients and 8% of PMF patients (36).  
The characteristics of patients with both JAK2 and MPL mutations are different from those with only the JAK2 in that there 
are no features of prodromal PV at diagnosis, they do not evolve into overt PV during follow-up, don’t have deranged EPO 
and ferritin levels and have different bone marrow characteristics(65).  
 
2.5.3. CALR 
This mutation was only discovered in 2013. In frequency, it is the second most common JAK-STAT activating mutation after 
the JAK2V617F (63). CALR mutations are absent in PV, occur in up to 35% of PMF and 24% of ET patients (36) but are 
mutually exclusive with both JAK2 and MPL mutations.  
 
The clinical significance of this mutation is that in both ET and PMF, patients with the CALR as opposed to JAK2 or MPL 
mutations, had longer overall survival, and a lower risk of death. CALR mutations are present in up to 73%  of patients who 
Distribution of JAK2, MPL, and CALR Mutations in  
Philadelphia Chromosome-Negative Myeloproliferative Neoplasms 
FIGURE 0.
REFERENCE 
































3. JAK2 V617F in Haematological Disorders other than Philadelphia negative MPN 
 
Although the JAK2 mutation provides clear evidence for malignant, clonal haematopoiesis, it is non-specific to the 
Philadelphia negative MPN, being described in low frequencies in other myeloid, but not in lymphoid malignancies(Kesler, et 
al 2000, Kiladjian 2012, Levine, et al 2005a).  
 
In the general population the prevalence was 0.2%(Nielsen, et al 2011).  
 
Patients with the MDS/MPN overlap group present with both features of dysplasia and marrow proliferation. Hereby 
included is CMML, MDS/MPN-unclassifiable and RARS-T and atypical CML (aCML).  
 
These disorders are rare – chronic myelomonocytic leukaemia (CMML) incidence is 0.3 per 100 000 in the US 
annually(Rollison, et al 2008).  Only 8% of them in turn contain a JAK2 mutation(Kiladjian 2012).  In RARS-T the finding of 
JAK2 (60%) and MPL mutations (10%) have been cause for debate whether it truly is a separate entity or a not simply a 
special form of ET due to the similarity of their phenotype(Gerds 2014, Malcovati, et al 2009). In CML, extraordinary case 
reports only exist where BCR-ABL and JAK2 occur concomitantly. It is also exceedingly rare in aCML(Wang, et al 2015, 
Zhou, et al 2015).  
 
In AML it seems the JAK2 is most common in patients who transform from a pre-existing MPN although de novo events have 
been described(Levine, et al 2005a).  
 




4.  Exploring the three major groups within MPN 
 
4.1. Polycythaemia Vera (PRV) 
PRV is distinguished from other causes of erythrocytosis by its clonal mechanism. Up to 95% of PRV is JAK2 V617F positive,  
but another 4% of PRV cases have their mutation within exon 12 (Michiels, et al 2015, Passamonti 2012, Stein, et al 2014).   
 
PRV patients have a reduced  life expectancy compared to the normal population, mainly from cardiovascular complications 
or disease transformation(Stein, et al 2014). Two-thirds present from 50 years onwards(Passamonti 2012, Passamonti, et al 
2003, Vannucchi 2014b).  They are frequently symptomatic with a wide range of problems, as evidenced in figure 1 (de 




PRV is diagnosed according to the WHO criteria of 2008(Passamonti 2012, Tefferi and Vardiman 2008b). An FBC is a 
relevant starting point and panmyelosis is more predictive of PRV than an isolated erythrocytosis(Passamonti 2012). An 
associated splenomegaly, usually not massive, associated with a panmyelosis also tips the scale more in favour of PRV. The 
patient’s presentation, and clinical information collected at the time will influence the diagnostic approach to 
erythrocytosis(Vannucchi 2014b). 
 
4.1.1. Haemoglobin(Hb) and haematocrit(Hct) Debate 
Hb, Hct and red cell mass (RCM) all act as surrogate markers of an elevated red cell mass in erythrocytosis(Johansson, et al 
2005). A fierce debate still rages regarding which of the 3 red cell parameters should be used as a diagnostic hallmark of 
PRV.  
 
The 2008 WHO criteria included Hb instead of Hct, and left a backdoor open with Hct more than 99th percentile 
acknowledged as equivalent(Tefferi and Vardiman 2008b). However, directly opposing opinions are reflected in the 
literature(Alvarez-Larran, et al 2012, Jacob, et al 2012, Johansson, et al 2005).  
 
The only consensus currently exists where values are conspicuously elevated. The BCSH guidelines states that males 
presenting with sustained Hct values >60% (Hb >18.5g/dL) or female with Hct>56% (Hb>16.5g/dL) could be assumed to 
have an absolute erythrocytosis and therefore do not require confirmatory studies (Barbui, et al 2014c, McMullin, et al 
2005, Vardiman, et al 2009).  
 
4.1.2. The 2008 WHO criteria (Vardiman, et al 2009) is the current standard of diagnosis, (Passamonti 2012, Tefferi and 
Barbui 2015, Vannucchi 2014b) shortly to be revised (Barbui, et al 2014c, Silver, et al 2013) .  
 
* Once classical constitutional symptomatology like night sweats or weight loss appear, the concern of transformation develops
Symptoms of PRV 
FIGURE 1.
REFERENCE 
De Lacerda JF, Oliveira SN, Ferro JM. Chronic myeloproliferative diseases. Handb Clin Neurol. 2014;120:1073-81 
Passamonti F. How I treat polycythemia vera. Blood. 2012;120(2):275-84 







7. Weight loss* 
8. Night sweats* 
9. Fatigue*
• Arterial (Ischaemic stroke, Transient ischaemic attack, 
myocardial infarction)
• Venous (Deep venous thrombosis, pulmonary embolism)




The JAK2 mutations simplified the diagnosis, necessitating investigation only in the mutation negative group(McMullin, et al 
2007). Some authors still advocate ruling out acquired erythrocytosis prior to JAK2 when faced with an isolated 
erythrocytosis, based on the clinical history obtained(Passamonti 2012, Vannucchi 2014b), including abdominal imaging, 
lung functions, chest X-ray, polysomnography depending on factors like heart/lung co-morbidities, obesity, smoking, and 
suspicion of hepatic/renal tumours. 
Polycythemia vera major criteria Polycythemia vera minor criteria
•Hemoglobin >18.5 g/dL (men) >16.5 g/dL (women)* 
•Presence of JAK2 V617F or similar mutation
• Bone marrow trilineage myeloproliferation 
• Subnormal serum erythropoietin level 
• Endogenous erythroid colony growth
* Hemoglobin or hematocrit values above the 99th percentile of the reference range for are, sex, or attitude of residence; or red 
cell mass >22% above mean normal predicted or hemoglobin >17g/dL (men), or >15 g/dL (woman) if associated with sustained 
increase of ≥2g/dL from baseline that cannot be attributed to correction of iron deficiency. 
Diagnosis of polycythemia vera requires mee7ng both major criteria and one minor criterion or the first major criterion and 
two minor criteria
2008 WHO PRV criteria 
FIGURE 2.
REFERENCE 
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization 
(WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
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4.1.3. The 2008 WHO algorithm for PV (Tefferi and Vardiman 2008b) starts with JAK2 & s-EPO measurement: 
 
4.1.4. Serum erythropoietin levels (sEPO) 
Erythropoietin is the principal hormone regulating erythropoiesis, secreted by the kidney in adults. The major stimulus for 
EPO is low O2 saturation due to anaemia, or hypoxemia(Messinezy M 2002).  
 
sEPO has been controversial because of conflicting results in the literature about the reliability and specificity of a low sEPO 
level. The big issues were a lack of standardisation of the test, and heterogeneity in methods by major studies, hindering 
comparison(Mossuz P 2004). On its own, is could be confusing because a low sEPO is suggestive, but not specific of PRV. A 
normal sEPO does not exclude PRV(Silver, et al 2013, Spivak and Silver 2008).   
 
Most experts in the field today include sEPO in their erythrocytosis algorithms as a useful adjunct, done concomitantly with 
the JAK2.  A low sEPO strongly eludes to an autonomous mechanism, and is expected where the JAK2 mutation is detected. 
Even in the absence of the JAK2, a low sEPO would be a motivating factor for requesting further genotyping in the form of 




Diagnostic algorithm for suspected polycythemia vera. Key: SP, secondary polycythemia; CP, congenital polycythemia; EpoR, 
erythropoietin receptor; VHL, von Hippel-Lindau; c/w, consistent with. 
2008 WHO PRV algorithm 
FIGURE 3.
REFERENCE 
Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization 
criteria and point-of-care diagnostic algorithms. Leukemia (08876924). 2008;22(1):14-22














EPO normal or ↑
















BM biopsy &  
JAK2 exon 12  
mutaKon screening
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4.1.5. Red cell mass (RCM) 
Erythrocytosis can be either true or apparent. Mechanisms for true erythrocytosis includes primary (autonomous) or 
secondary factors. Using the nuclear medicine RCM and plasma volume  determination helps differentiate between absolute 
and apparent erythrocytosis(Lorberboym, et al 2005).  
 
The hallmark of true polycythaemia or erythrocytosis is an increased proportion of red blood cells(RBC) in the peripheral 
blood in relation to plasma volume. In apparent polycythaemia a lowered plasma volume with an increased or normal RCM 
skews the ratio. Surrogates of red cell volume, including Hb, Hct and red cell count may not always reflect the total RCM 
because of variations in plasma volume.  
 
RCM limitations are well recognized, but it’s biggest drawback is that not all centres have access to this valuable resource. 
Nevertheless, where available, it remains widely employed and is still accepted as the gold standard for determination of the 
red cell mass. Furthermore, as a test it is also cumbersome, and lacks precision in obese individuals, in states of dehydration 
and even in patients on commonly prescribed medication like diuretics (Barbui, et al 2014c, Spivak and Silver 2008).  
 
Marked disagreements regarding the utility of RCM existed before the JAK2 discovery and continues to divide the 
haematological community. Supporters of RCM are adamant that it is to remain in the guidelines, provided the prescribed 
method is used and the indication is to detect suspected early cases. Opponents of the nuclear medicine RCM/plasma 
volume test, argue that its limitations exceed its benefits and that other tests incl. bone marrow histology, sEPO and biologic 
markers have made it redundant(Tefferi 2005). 
 
4.1.6. Bone marrow biopsy (BMB) 
BMB is not compulsory for the diagnosis of PRV.   
 
The rationale for BMB in the investigation of erythrocytosis is dependent on the clinical scenario(Vannucchi 2014a).  It is 
most useful in cases where the diagnosis is in doubt(Barbui, et al 2014c). 
 
4.1.7. Endogenous erythroid colonies (EEC) 
Mention has to be made of this investigative modality, however it was already in 2008 declared as “a research tool of historic 
interest”(Spivak and Silver 2008), only available in research laboratories(McMullin, et al 2005).  
 
4.1.8. Utility of phlebotomy (venesection) 
A procedure in use since antiquity, venesection has both therapeutic and preventative roles. Lowering the haematocrit 
reduces blood viscosity and may be useful in all forms of erythrocytosis, though sparse evidence exists. Apart from its role in 
erythrocytosis/PRV, it is also used in haemochromatosis and porphyria cutanea tarda(Cook 2010, Randi, et al 2015).  
 
In PRV, phlebotomy is accepted as the mainstay of treatment with cytoreductive therapy as a supportive therapy. But who 
else should be venesected? 
 
According to Assi et al(Assi and Baz 2014), relative polycythaemias incl. Gaisbock’s syndrome, patients with tumours, living 
at altitude, Cushing’s syndrome, on exogenous steroid replacement (iatrogenic or illegal!) and smokers are not eligible. 
Unfortunately, no sources for these statements are supplied.  
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Eligible patients according to this article are in hypoxic heart or lung conditions, including chronic obstructive pulmonary 
disease. The latter is, however, mostly related to smoking and smokers were included on the list of ineligibles.  No reasons 
are also given as to why one should be eligible or not. Apart from these disparities, renal transplant patients with 
erythrocytosis and poorly controllable blood pressures, as well patients with cyanotic heart disease are listed as eligible. 
Unfortunately, due to the inconsistencies mentioned, this article is not completely sound.  
 
Other articles focus more on the use of phlebotomy in proven PV, but there is a paucity of information for those with 
secondary causes of erythrocytosis on the indications, benefits or disadvantages of phlebotomy.  
 
4.1.9. A Perplexing Entity: “Idiopathic Erythrocytosis” 
Idiopathic erythrocytosis is an absolute erythrocytosis with no known cause, diagnosed by exclusion of primary and 
secondary erythrocytosis. Absolute erythrocytosis is defined as an increase in the RCM >125% of the predicted value for 
the body mass of the patient, or surrogate markers i.e. Hb and Hct with values as mentioned.  
 
 
Once the myriad known causes have been excluded, a large group of patients remain in whom no mechanism for the 
erythrocytosis has been identified, labelled idiopathic erythrocytosis (IE). Prior to the discovery of the JAK2 clone, many 
PRV patients were classified in this group.  Ironically it still is the most common type of erythrocytosis in clinical practice, but 
Causes of an Erythrocytosis 
FIGURE 4.
REFERENCE 








1. 2. Idiopathic  Erythrocytosis3.
Congenial Acquired (EPO-mediated)
Central Local hypoxia Pathologic EPO  
producEon
Drug associated
• Chronic lung disease 
• R-L* cardiopulmonary 
vascular shunts 
• CO* poisoning 
• Smoker’s 
erythrocytosis 














• EPO Doping 
• Androgens
• EPO receptor 
mutaEon
• PRV • MutaEons: VHL, 
PHD2, HIF-2a. 
• High O2-affinity Hb 
• Bisphosphoglycerate 
mutase deficiency
* R-L, right to left; CO – carbon monoxide; OSA – obstructive sleep apnoea; RAS – renal artery stenosis; ESRD – end-stage renal 
disease; CA – carcinoma; HCC – hepatocellular carcinoma
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has been poorly studied in the literature compared to PRV and prominent authors such as Tefferi cautions against applying 
the term too eagerly (Finazzi, et al 2006, McMullin 2009, Pearson and Messinezy 2001).   
 
It is thought that these patients could conceivably harbour an exceedingly rare form of congenital erythrocytosis or JAK2-
wild type PRV form, which is beyond the scope of this article(Randi, et al 2015). 
 
Clinical characteristics of this group is discordant and inconsistent. One third has low-, two-thirds normal EPO values. 
Management is on an individual basis, taking into account other cardiovascular and background risk factors for thrombosis. 
Phlebotomy may/may not be of value. An arbitrary cut-off of Hct 54% exist beyond which phlebotomy is considered, aiming 
for values between 45-50%, depending on practicalities. Cytoreductive treatment is unanimously rejected in those without 
evidence of a malignant clone(McMullin 2009).  
 
 
4.2. Essential Thrombocytosis (ET) 
The presence of a chronic state of thrombocytosis in which reactive causes have definitively been excluded, as well as the 
inability to ascribe the thrombocytosis to one of the other MPN subgroups (PMF, PRV) is what defines ET(Harrison and 
Green 2003). The WHO defines the cut-off as >450 x 109/L with extreme thrombocytosis as platelets of >1000 x 109 
(Bleeker and Hogan 2011). 
 
4.2.1. The 2008 WHO criteria(Vardiman, et al 2009) for the diagnosis of ET, as follows: 
 
Patients who present with an increased platelet count are a heterogeneous group, with multiple conditions which could 
manifest this way. Harrison et al stated the position clinicians and researchers alike were faced with, eloquently: “The major 
2008 WHO criteria for ET 
FIGURE 5.
REFERENCE 
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization 
(WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
Platelet count ≥ 450 x 109/L
Major criteria
1.
Megakaryocyte proliferaEon with large and mature morphology
Not meeEng WHO criteria for PRV, PMF, CML, MDS or other myeloid neoplasm
Presence of JAK2 V617F or other clonal marker and no evidence of reacEve 
thrombocytosis
Diagnosis of ET requires 




1.= + 2. + 3. + 4.
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difficulty in making a diagnosis in ET is the lack of a definitive position criterion analogous to the presence of BCR/ABL 
transcripts in CML(Harrison and Green 2003). 
 
The first step is therefore to carefully evaluate and rule out the causes of a reactive thrombocytosis as well as to ascertain 
the persistence (chronicity) of the thrombocytosis. Comorbidities, history, other features of the FBC and past platelet 
counts have to be taken into consideration(Bleeker and Hogan 2011).  
 
Causes can be broadly divided into spurious, reactive or clonal, with reactive by far the most common cause(Beer, et al 2011, 
Bleeker and Hogan 2011). Reactive and clonal conditions can co-exist, especially in persistent thrombocytosis(Bleeker and 
Hogan 2011). Measuring circulating acute phase reactants is not always reliable as they may have returned to normal by the 
time the thrombocytosis is detected(Folman, et al 2001). Iron-deficiency anaemia need to be ruled out, with s-ferritin and 
transferrin to be demonstrated normal before moving on to other causes. The following table illustrate the potential causes 





Once reactive or spurious causes have been excluded, the investigator can move on to the next phase. Regretfully, this is 
where the WHO start their algorithm of investigation, which is a pity, since it skips a number of basic steps, including history 




Causes of a Thrombocytosis 
FIGURE 6.
REFERENCE 














• Blood loss or iron 
deficiency 




• Drug effect* 





• Mutations in MPL, 







• Red cell fragmentation
* e.g. Vincristine, adrenaline, all-trans-retinoic-acid 
* * accompanying myeloid/lymphoid neoplasia
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4.2.2. 2008 WHO algorithm for ET(Tefferi and Vardiman 2008b) 
 
 
In ET, a BMB is mandatory, even where JAK2 is positive. This provides confirmation of  the diagnosis (vs. PMF), prognostic 
information and serves as a useful baseline if the patient later undergoes transformation(Beer, et al 2011). 
 
In the molecular era following the JAK2 discovery pinning it down to a clonal mechanism has been promoted, as JAK2 is 
prevalent in 55% of ET cases(Tefferi and Barbui 2015). In an additional 8% of cases the MPL mutation (which interestingly 
was discovered antecedent to the JAK2) also tests positive(Michiels, et al 2015). 
 
The majority of ET patients is female with diagnosis around 60 years. The true prevalence of ET is uncertain because 
patients are shown to have a normal life-expectancy(Fenaux, et al 1990).  
 
Presentation is with a wide range of symptoms, from vasomotor-like (dizziness, headache, atypical chest pain, syncope, visual 
disturbances, paraesthesia and even erythromelalgia as in PRV), but also with thrombosis and bleeding, as well as pregnancy 
complications(Bleeker and Hogan 2011). 
 
4.2.3. Complications of ET 
Compared to reactive thrombocytosis, where the risk of thrombotic complications are proven to be low, in PV & ET 
thrombosis is a cause of major morbidity and mortality and the main factor in determining treatment approach(Bleeker and 
Hogan 2011, Elliott and Tefferi 2005, Marchioli, et al 2005). Even patients on cytoreductive treatment continue to suffer 
2008 WHO algorithm for ET 
FIGURE 7.
REFERENCE 
Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization 
criteria and point-of-care diagnostic algorithms. Leukemia (08876924). 2008;22(1):14-22
Peripheral blood mutation screening for JAK2 V617F
V617F (+) V617F (-)
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from thrombosis. Age is also a significant risk factor, as well as ET and PRV patients with a concomitant leukocytosis(Bleeker 
and Hogan 2011). 
 
Other manifestations of ET include bleeding tendencies and transformation. Bleeding has especially been noted in extreme 
thrombocytosis (Beer, et al 2011, Ozer, et al).  
 
ET patients also have more pregnancy-related morbidity, with intra-uterine growth retardation, stillbirth and pre-eclampsia 
in up to 25-50% of pregnancies. JAK2-positive ET patients have an even higher rate(Beer, et al 2011, Passamonti, et al 2007) 




Complications of essential thrombosis 
FIGURE 8.
REFERENCE 
Beer PA, Erber WN, Campbell PJ, Green AR. How I treat essential thrombocythemia. Blood. 2011;117(5):1472-82. 
Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, et al. Increased risk of pregnancy complications in patients with 
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4.3. Primary Myelofibrosis(PMF) 
PMF is the least common of the MPN’s. It is difficult to define as an entity, because the disease process could be a result of 
multiple causes. Up to recently, not even the name could be agreed upon: primary chronic myelofibrosis (PMF), idiopathic 
myelofibrosis (IMF) or myelofibrosis with myeloid metaplasia (MMM) were all synonyms (Okamura 2003). Some authors 
even claim that “biologically, there is no such thing as ‘primary’ myelofibrosis”(Spivak and Silver 2008).  
 
In PMF clonal myeloproliferation is accompanied by a secondary inflammatory state characterized by bone marrow stromal 
changes and abnormal cytokine expression(Tefferi 2011). Bone marrow fibrosis can, however, be due to both haematologic 
and non-haematologic conditions as summarised in figure 9. Even within MPN, a phenotypically similar entity exist with 
post-PRV or post-ET fibrosis(Tefferi 2011). However, a distinction is made by Tefferi in referring to “myelofibrosis” only in 
terms of PMF, and with every other cause the phrase “with bone marrow fibrosis”, i.e. “MDS with bone marrow 
fibrosis”(Tefferi 2011).  
 
 
Causes of Bone Marrow Fibrosis 
FIGURE 9.
REFERENCE 
Tefferi A. How I treat myelofibrosis. Blood. 2011;117(13):3494-504.
Haematological Non-haematological
• Primary myelofibrosis 
• Post ET-fibrosis 
• Post PRV-fibrosis 
• Hereditary thrombocytosis  
(germline mutations) 
• Other myeloid neoplasms 
• Lymphoid neoplasms
• Metastatic cancer 
• Autoimmune disease 
• Vit D deficiency 
• Hyperparathyroidism 
• Pulmonary hypertension 
• Infections (AIDS, Leishmaniasis) 
• Toxins (thorium dioxide) 
• Treatment with growth factors  
• Gray platelet syndrome
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Average age at diagnosis is 66 years. Males are predominantly affected in 3:2 fashion(Tefferi, et al 2012). Typical symptoms 
and causes of morbidity  are summarised below in figure 10  (Tefferi 2014). PMF is debilitating and chronic with a reduced 





Once PMF is suspected on the basis of the clinical presentation, a BMB becomes mandatory to elucidate the morphologic, 
cytogenetic and molecular characteristics. As illustrated with the wide differential diagnosis, simply illustrating marrow 
fibrosis does not confirm PMF(Tefferi 2011).  
 
A number of mutations are also associated with PMF, none of them, however, are PMF-specific(Tefferi, et al 2012). JAK2 is 
detected in 50-60% of PMF cases, MPL in 8%, and in the mutually exclusive group, a further 35% are CALR-



















Symptoms of PMF 
FIGURE 10.
REFERENCE 
Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(9):
915-25.
1. Severe anaemia 
2. Hepatosplenomegaly 
3. Constitutional  
4. Pruritus 
5. Splenic infarcts 
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7. Thrombosis 
8. Bleeding 
9. Portal hypertension sequelae 
10. Non-Hepatosplenic  
extramedullary haematopoiesis
• Fa/gue, weight loss/ cachexia, night sweats
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2008 WHO criteria for PMF 
FIGURE 11.
REFERENCE 
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization 
(WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
Major criteria Minor criteria
• Megakaryocyte proliferation and atypia 
accompanied by reticulin ± collagen fibrosis, 
or in the absence of overt fibrosis, 
megakaryocyte must be accompanied by 
increased marrow cellularityand granulocyte 
proliferation (i.e. prefibrotic myelofibrosis) 
• Not meeting WHO criteria for PRV, CML, 
MDS or any other myeloid neoplasm 
• Presence of JAK2 V617F or other clonal 
marker and no evidence of reactive marrow 
fibrosis
• Leukoerythroblastosis 
• Increased serum LDH 
• Anaemia 
• Palpable splenomegaly
Diagnosis of PMF requires all 3 major criteria and 2 minor criteria
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2008 WHO algorithm for PMF 
FIGURE 12.
REFERENCE 
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization 
(WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
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5. Spectrum of MPN - Overlap between PRV/ET/PMF 
 
It is not always easy to distinguish the origin of the MPN proven by a JAK2 mutation. Multiple overlaps in clinical 
presentation and evolution exist, as these illustrations, borrowed from Kilidjian et al. (Kiladjian 2012) demonstrate. The 
suggestion has been made whether V617F positive ET/PMF/PRV did not simply evolve according to a continuum model in 




Particular controversy often arises during the attempted diagnosis of ET because of its heterogeneity and the need to 
exclude other disorders. Distinguishing the border between ET and early “pre-fibrotic” PMF is complex, and some has even 
debated the traditional view of separate entities. The main arguments are: ET myelofibrosis and PMF are clinically 
indistinguishable, they share JAK2 and MPL mutations, and thrombocytosis often predates the PMF diagnosis by many 
years(Beer, et al 2011).  
 
Furthermore, phenotypic overlap also exists between PRV and ET, and uncertainty reigns about where to draw the line 
between them. ET patients certainly could have a raised Hct, and PRV patients a thrombocytosis. For simplicity, Beer et al. 
recognised this problem but still classified patients with a positive JAK2 and and a raised Hct as PRV(Beer, et al 2011). In the 
absence of specific diagnostic biologic markers, the evaluation and final diagnosis has to be based on expert 
judgement(Spivak 2003). 
Characteristics and Complications Overlap between MPN subgroups 
FIGURE 13.
REFERENCE 
Adapted from Kiladjian JJ. The spectrum of JAK2-positive myeloproliferative neoplasms. Hematology Am Soc Hematol Educ 
Program. 2012;2012:561-6.










Taking into account the spectrum of disease represented by a JAK2 mutation, it is clear that JAK2 only unambiguously 
provides evidence of malignant, clonal and finally, myeloid haematopoiesis.  
 
6. JAK2 V617F mutation in the presence of thrombosis 
 
Clutching at straws for a cause? 
Thrombophilia denotes conditions that are associated with an increased risk of thromboembolism, hypercoagulable state or 
variations in the fibrinolytic system(Smalberg, et al 2011).  
 
The understanding of the aetiology of thrombosis has improved over the years and finding a cause is a challenge the 
physician is frequently faced with. It is multifactorial, and seldom with only a single risk factor present (Smalberg, et al 2011). 
MPNs, especially PV and ET are now recognized as acquired risk factors in the aetiology of thrombosis (Klampfl, et al 2013, 
Smalberg, et al 2011).  ET patients will have up to 50% incidence of thrombosis within a decade of diagnosis, predominantly 
arterial. Splanchnic thrombosis is characteristic of MPN, particularly in young women, and, to a lesser extent, the cerebral 
circulation(Martinelli, et al 2014, Schafer 2004, Whitlatch and Ortel 2008).  
 
Despite the multifactorial aetiology of DVT or PE, thrombosis at unusual sites like the splanchnic veins more often raises 
questions about underlying causes(Martinelli, et al 2014).  
 
Splanchnic Vein Thrombosis  
The Budd Chiari syndrome (BCS) and portal vein thrombosis (PVT) are grouped under splanchnic thrombosis(Janssen and 
Leebeek 2006, Smalberg, et al 2012). 
 
MPNs are the most common underlying cause and can be identified in nearly 30-50% of BCS and 15-30% of PVT patients. 
(Colaizzo, et al 2007, De Stefano, et al 2007, Dentali, et al 2009a, Kiladjian, et al 2008, Smalberg, et al 2011) In both 
conditions the peripheral blood count changes may be masked, owing to portal hypertension and consequences thereof i.e. 
hypersplenism, iron deficiency and haemodilution, therefore the conventional criteria of MPN are of limited value(Janssen 
and Leebeek 2006, Smalberg, et al 2011). “Occult MPN” refers to them, and previously the clinician only had limited means 
to rely on for making the diagnosis(Smalberg, et al 2012).   
 
Screening for JAK2 rendered a new diagnostic tool and has since been indispensable in the routine diagnostic workup of 
these conditions. In contrast, the JAK2 exon 12 and MPL mutations have no specific association with splanchnic vein 
thrombosis and should not be routinely screened for. Why the MPNs and JAK2 are so strongly analogous to splanchnic vein 
thrombosis  remains a mystery (Smalberg, et al 2012). 
 
 
Other sites of thrombosis 
It remains puzzling why patients with similar prothrombotic factors develop diverse forms of thrombosis.  Why does one 
person develop a DVT/PE and another a splanchnic thrombosis? Local factors are potentially involved in the pathogenesis of 
thrombosis at specific sites, but the underlying mechanisms elude us (Smalberg, et al 2011). In 2009, a meta-analysis 
appraised the role of JAK2 in various forms of thrombosis, incl. SVT, DVT of lower limbs or PE, cerebral vein thrombosis, and 
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retinal vein thrombosis. A strong association between JAK2 and splanchnic vein thrombosis was found, but its prevalence in 
the other forms of idiopathic VTE was no different to that of the general population(Dentali, et al 2009a, Shetty, et al 2010). 
 
 
Cerebral sinus venous thrombosis (CVT) 
The incidence of CVT is uncertain because epidemiological studies are lacking. Young female adults are mostly affected. The 
superior sagittal and transverse sinus are mostly involved, but in two-thirds of case more than one sinus is 
involved(Martinelli and De Stefano 2010).  
 
Martinelli et al. (Martinelli, et al 2014) looked particularly at the characteristics and course of CVT  in MPN patients. In their 
study, CVT complicated MPN in ± 1% of cases. Also relevant is that ET patients with the JAK2 mutation were especially at 
risk. Nearly half of their patients with CVT were diagnosed with the two conditions concomitantly, but regretfully, no 
mention is made of the FBC characteristics at the time of diagnosis (i.e. was there a clue in the counts eluding to an MPN?). 
 
In a meta-analysis by Dentali et al., JAK2 had a prevalence of 2.57% in CVT. This is slightly increased from the presence of 
the mutation in the general population. Compared to the corresponding 32% in SVT, it is clear that blindly screening for 
JAK2 is less justified(Dentali, et al 2009a).  
 
 
Venous PE & lower extremity DVT 
Risk factors for common venous thromboembolism (VTE) are eloquently summarized by Smalberg et al (Smalberg, et al 
2011). Herein it shows that stronger risk factors (Protein C-, antithrombin deficiency, antiphospholipid antibodies, 
malignancy, immobilisation, surgery and obesity) carry more weight than weaker risk factors like MPN, hormonal factors or 
autoimmune disease. Investigations should therefore focus on stronger factors first.  
 
 
Hospitalised and cancer  patients are particularly known to have multiple risk factors for common VTE – see figure 14 
(Smalberg, et al 2011). It follows naturally that age-appropriate screening is undertaken in patients who present with 
idiopathic VTE, especially if recurrent(Whitlatch and Ortel 2008). In contrast to the risk factors summarised in figure 14, the 
Risk factors for Thromboembolism 
FIGURE 14.
REFERENCE 
Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, de Maat MP. Hypercoagulability and hypofibrinolysis and risk of 
deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol. 2011;31(3):
485-93.
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mean prevalence of MPN in VTE is only 0.88%. Dentali et al. conclude that patients with VTE should not be screened for the 
presence of the JAK2 mutation, as the yield is nearly negligible(Dentali, et al 2009a). 
 
 
Upper Extremity Thrombosis 
A high degree of mobility in the upper limbs is often quoted as a reason why thrombosis here is relatively rare. The 
subclavian vein is most often involved.  Causes are elaborated on in figure 15 (Martinelli and De Stefano 2010). No specific 




Retinal Vein Thrombosis (RVT) 
RVT refers to occlusion in the central retinal vein(CRVO) or in a branch retinal vein (BRVO). RVT occurs similar in both 
sexes, commonly in advanced age, and usually unilateral. It shares traditional systemic risk factors for thrombosis, i.e. 
hypertension, diabetes and arteriosclerosis. Screening for thrombophilia in RVT produced conflicting results, where factor V 
Leiden and prothrombinG20210A are not associated, but antiphospholipid antibodies and hyperhomocysteinaemia are 
proven as risk factors(Martinelli and De Stefano 2012).  
The JAK2 prevalence in RVT was only 0.99% in the Dentali’s meta-analysis(Dentali, et al 2009b). Hermans unambiguously 
concluded that  JAK2 is not implicated in this scenario with his article “The JAK2 V617F mutation is not a cause of of central 




Risk factors for Upper Limb thrombosis 
FIGURE 15.
REFERENCE 
Martinelli I, De Stefano V. Rare thromboses of cerebral, splanchnic and upper-extremity veins. A narrative review. Thromb 
Haemost. 2010;103(6):1136-44.
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The discovery of the JAK2 V617F mutation came as an exciting development in Haematology already in 2005, and even 
though several years have gone by wherein this test had been available in our hospital there had been no data available on 
utility in our unique South African setting. Instead, we still have to rely on European and American information. We reviewed 
the literature on the various subgroups within MPN (i.e. PRV, ET and PMF) and the guidelines that sprung forth since 2005 
and in our study, aimed to apply them retrospectively to the patients that were already under our care. Our objectives were 
confined to the diagnostic aspects of MPN and the investigative approach to an elevated haemoglobin and platelet count. 
 
With regards to erythrocytosis we studied the debates raging within the Haematological community on the use of surrogate 
markers for absolute erythrocytosis and the use of ancillary measures such as the nuclear RCM and sEPO. We identified a 
significant group of patients during our study where the aetiology of the erythrocytosis seemed unclear, and reviewed the 
available literature on the entity of idiopathic erythrocytosis. 
 
The presence of the JAK2 V617F mutation and the prevalence of thrombosis and its respective aetiology were also 
reviewed, in order to determine whether the widespread use of this mutation in thrombosis was justified and apply these 
findings in the future to the patients under our care. 
 
Gaps identified in the literature were the striking paucity of information available on the effects of androgen therapy on the 
Hb/Hct, as well as the influence on these markers following a splenectomy. It became very apparent that “smoker’s 
polycythaemia” remains a poorly delineated concept where the overlap with early chronic lung disease is difficult to define. 
Even less consensus exist regarding the application of venesection in erythrocytosis groups where a clonal mechanism could 
not be identified.  
 
In conclusion, we conducted a broad overview of literature surrounding the clonal marker of JAK2 V617F and attempted 
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CHAPTER TWO  




ROLE OF THE JAK2V617F MUTATION ANALYSIS IN THE DIAGNOSTIC 




We studied the implementation of JAK2 mutation analysis in conjunction with the World Health Organisation (WHO) 
guidelines in the pathway to MPN diagnosis in 279 patients presenting with one of three clinical scenarios: erythrocytosis, 
OR leukocytosis and/or thrombocytosis and/or splenomegaly; OR patients with thrombosis without cytoses. Patients were 
investigated for MPN and managed in the haematology clinic of Groote Schuur Hospital. We studied the association of 
clinical and laboratory variables with clonal vs non-clonal diagnoses. In 120/297 patients MPN was confirmed: Polycythemia 
vera (PV), (n=51, 100% JAK2 mutated); essential thrombocytosis, (n=41, 42% JAK2 mutated); primary myelofibrosis (n=28, 
57% JAK2 mutated). The 2016 WHO haemoglobin/haematocrit thresholds in PV were validated. Idiopathic erythrocytosis 
(IE) found in 44 patients. Bone marrow histology, but not serum EPO level, was essential to differentiate between clonal and 
non-clonal erythrocytosis. Both PV and IE patients complied with the criteria of absolute erythrocytosis on peripheral blood, 
yet nuclear red cell mass identified critical differences between clonal and non-clonal erythrocytosis. No patient venesected 
for non-clonal erythropoiesis developed thrombocytosis. JAK2 mutation analysis applied with the WHO diagnostic 
algorithm efficiently differentiated true clonal myeloproliferation from reactive cytoses. Lifestyle and metabolic factors such 
as smoking and thrombosis were not associated with either clonal or non-clonal erythrocytosis, and were equally present in 
mutated and unmutated essential thrombocytosis. 
 
Introduction 
The Philadelphia-negative classic myeloproliferative diseases mainly comprise essential thrombocytosis (ET), primary 
myelofibrosis (PMF) and polycythaemia vera (PV)(Michiels, et al 2006). The molecular findings of the past decade have 
confirmed the clonal nature of the disorder – hence the name change to myeloproliferative neoplasms (MPN) (Baxter, et al 
2005b, James, et al 2005a, Kralovics, et al 2005, Levine, et al 2005b) The pivotal discovery of the JAK2 V617 mutation in 
2005(Spivak and Silver 2008) brought about a major advance in our ability to diagnose these three disorders. Previously, in 
many cases, it had been problematic to define the diagnostic distinction between a myeloproliferative neoplastic disease and 
a reactive proliferative disorder, but we can now confidently define the majority of these disorders based on the presence of 
this mutation. 
 
Regarding the application of the JAK2 mutation analysis in patients with suspected MPN, it is expected that up to half of 
patients with ET and PMF will be JAK2 negative(Tefferi and Barbui 2015). Newly emerging markers such as CALR and MPL 
provide further evidence of clonality and have implications for prognosis(Arber, et al 2016).Expert interpretation of the 
histology on bone marrow examination (BME) in close adherence to the World Health Organisation (WHO) diagnostic 
algorithm will confirm JAK2 negative ET and PMF and thereby rule out other causes of leukocytosis, thrombocytosis and 
splenomegaly(Tefferi and Vardiman 2008a).  
 
In patients investigated for erythrocytosis, one could argue that ascertaining a clonal diagnosis of PV should be fairly 
straightforward because more than 95% JAK2 positivity has been reported(Michiels, et al 2015, Passamonti 2012). 
Nevertheless, after confirming JAK2-positive PV and ruling out secondary causes of erythrocytosis, the clinician is 
confounded by a sizeable patient population with likely non-clonal, yet sustained erythrocytosis(McMullin 2012, Randi, et al 
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2016). The designation ‘idiopathic erythrocytosis’ is used for this patient population regarded to have an absolute 
erythrocytosis – defined as an increased red cell mass more than 125% of the predicted value – as expressed in either raised 
haemoglobin (hb) or haematocrit (hct), or nuclear red cell mass (RCM)(Pearson, et al 1995) (Johansson, et al 2005, McMullin, 
et al 2005). To outrule JAK2 negative PV, there is the WHO criterium for trilineage proliferation on BME. A low serum 
erythropoietin level (sEPO) is an important part of the diagnostic algorithm for PV, but it is unclear if it has additional value 
to substantiate true clonal erythropoiesis(Barbui, et al 2015, Mossuz, et al 2004). 
 
We studied the implementation of the JAK2 mutation analysis, in conjunction with the diagnostic algorithm for respectively 
PMF, ET and PV, in the patient population of our tertiary referral center. We wanted to see firstly how the JAK2 test would 
be distributed in our three Philadelphia-negative MPN populations. However, we were equally interested in the rest of the 
population who were tested and an MPN ruled out. If this population can be better defined, we reasoned that it could inform 
a more targeted utilization of the JAK2 test in our institution. In this regard we examined if smoking and a new malignancy 
were more closely associated with the reactive or non-clonal conditions. Likewise the relationship of leukocytosis or 
thrombocytosis with clonal versus non-clonal erythrocytosis was of interest(Randi, et al 2016).  
 
Therefore, our second aim was to analyse patients within the subgroups based on the clinical reasoning behind requesting 
the JAK2 test. JAK2 mutation analysis was requested based on three specific indications, firstly in patients investigated for a 
myeloproliferative neoplasm due to the presence of erythrocytosis, secondly based on leukocytosis and/or thrombocytosis 
variably associated with splenomegaly; and thirdly, in patients where the occurrence of a thrombotic episode prompted 
investigation. Although the occurrence of a thrombotic episode is often the first step leading toward a diagnosis of MPN, 
nevertheless it is only in splanchnic vein thrombosis  that there is consensus that JAK2 mutation screening is 
indicated(Dentali, et al 2009a, Yonal, et al 2012). Our third aim was to determine the incidence of thrombosis in all patients 
at diagnosis and to correlate it with their underlying disorder. This would additionally determine if thrombotic episodes in 
absence of cytoses ever led to a diagnosis of MPN in our population.  
 
Methods 
Patient cohort and clinical assessment criteria: 
We retrospectively analysed the clinical records of 279 patients who had been tested for the JAK2V617F mutation, as part 
of diagnostic investigation for MPN by the Division of Haematology (Department of Medicine) Groote Schuur Hospital, 
Cape Town during the period 2007 to 2014. Ethical consent was obtained by the University of Cape Town Health Faculty 
Research Ethics Committee (number 091/15). All clinical tests analysed were previously performed by the National Health 
Laboratory Service at Groote Schuur hospital, using accredited, standard methodology. Specifically, the JAK2 V617F 
mutation was detected by PCR amplification and melting curve analysis of the amplicons, using highly specific hybridization 
probes as described previously. The sensitivity in PV and ET was respectively 78% and 40 %(McClure, et al 2006). The RCM 
was measured using chromium 51-labeled red blood cells and iodine (125I)-labeled albumin, respectively, following the 




Clinical assessment was carried out within 3 groups based on clinical reasoning behind JAK2 mutation analysis test: 
1) Patients investigated for erythrocytosis (n=138): These patients had erythrocytosis with or without other cytoses.  
This included all patients with hb and hct values above local normal threshold values (>17g/dL and/or >48% for males 
and >16g/dL and/or >46% for females). We also recorded the higher World Health Organisation (WHO) thresholds 
(Vardiman, et al 2009) (hb in males > 18.5g/dL; females >16.5g/dL) as well as the two British Committee for Standards 
in Haematology (BCSH) thresholds (hct in males >52% and >60%; females > 48% and >56%)(McMullin, et al 2005).  
2) Patients investigated for cytosis (leukocytosis and/or thrombocytosis) or for splenomegaly (n=103): These patients 
presented with neutrophil leukocytosis and/or thrombocytosis and/or splenomegaly suspicious for MPN. The 
thresholds as given by our NHLS laboratory were as follows: platelets 178-400 x 109/L, white cell count 4.00 – 10.00 x 
109/L.  
3) Patients investigated primarily for thrombotic events (n=37): These patients were distinguished from the erythrocytosis 
and other cytoses groups in that blood counts were in the normal range.  
 
Clinical assessment was based on: 
• General and demographic data: age at date of JAK2 mutation analysis, gender, previous disease history, smoking 
history, clinical scenario leading to JAK2 test including new diagnosis of malignancy within six months of MPN 
diagnosis. 
• Review of MPN diagnosis: A diagnostic review for PV, ET or MPN or other MPN-related disorder was made on all 
patients using the diagnostic algorithm of the 2008 WHO based on history and clinical examination, full blood count 
(FBC) values at presentation and/or at date of JAK2 mutation testing as well as during follow-up, BME, spleen size, 
sEPO, and RCM result(Tefferi and Vardiman 2008a).  
• Thrombotic events: The prevalence of thrombotic events in the year before and at diagnosis was recorded in all 
patients. Thrombotic events included venous or arterial thromboembolism such as cerebrovascular, peripheral 
vascular and acute coronary events as well as venous thromboembolism. 
• Occurrence of cytoses on follow-up in erythrocytosis patients: We recorded platelets/leukocytes above normal 
laboratory values at diagnosis and again at follow-up during venesection we recorded the occurrence of 
thrombocytosis and leukocytosis and the need for cytoreductive therapy for leukocytosis/thrombocytosis. 
 
Statistical analysis: 
 Data was collected on a password-protect excel spreadsheet and analysed using Stata (Version 13.1; Stata Corp, College 
Station, Texas, USA).  Descriptive statistics was used to characterise the patient cohort, where continuous variables are 
expressed as mean (± standard deviation) when variables are normally distributed or median (interquartile range) for data 
that were skewed.  Categorical variables were represented using frequency distribution.  The two idiopathic erythrocytosis 
groups were combined in order to conduct a two-sample test of proportions for the difference in frequencies in smoking and 




Our cohort consisted of 158 (57%) male and 120 (43%) female patients; mean age at testing 51.0 years (female=52.7 years, 
male=50.3 years). Patients were analysed in the three modes of presentation as described under methods (Figure 1). Eighty-
six (31%) patients tested positive for the JAK2 mutation of whom 2 with myelodysplastic/myeloproliferative disorder 
	 40 
(MDS/MPN). An additional 36 patients were diagnosed with JAK2 negative MPN – in total 120 (43%) patients with MPN 
and 2 patients with JAK2 positive MDS/MPN. 
 
Patients Investigated For Erythrocytosis With or Without Other Cytoses (n=139):  
We subdivided patients presenting with erythrocytosis into 5 groups with regards to shared diagnostic characteristics as 
laid out below and in Figure 1. The five subgroups were clonal, idiopathic, transient, secondary and iatrogenic erythrocytosis. 
We then described shared characteristics between the groups in table 1, including:  diagnostic sEPO, measures used for 




1. Clonal erythrocytosis: JAK 2 positive Polycythaemia Vera (PV) (n=51). Thrombocytosis was present in 40 patients 
(78%) at diagnosis and leukocytosis in 30 patients (59%). All were venesected to keep hct<45, placed on aspirin if not 
contra-indicated, and 43 patients (84%) needed cytoreductive therapy to normalise platelet count.  
 
2. Idiopathic erythrocytosis (IE) (n=46). These patients had a sustained erythrocytosis, but none of them was JAK2 
positive. They had variable levels of sEPO as seen in Table 1. However, even in cases with low sEPO, the BME was not 
indicative of MPN and JAK2 negative PV was ruled out. Hb/hct values indicated sustained absolute erythrocytosis; 37 
patients (80%) were venesected during follow-up. Unless contra-indicated, patients were placed on aspirin but none 




























































PATIENTS PRESENTING WITH ERYTHROCYTOSIS 
FIGURE A.
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2.1. Idiopathic yet RCM proven apparent erythrocytosis (n=25). Patients in this group had a RCM study indicating a 
apparent or spurious erythrocytosis. 7 had thromboses at or prior to diagnosis. Thrombocytosis or leukocytosis 
was seen at diagnosis in only 2 patients. Thrombocytosis or leukocytosis developed in none of 18 patients 
venesected during follow-up.  
2.2. Idiopathic erythrocytosis (n=21). RCM was either not carried out in these patients, or confirmed an absolute 
erythrocytosis in 4 patients. No thrombocytosis was seen at diagnosis, and only 3 patients had leukocytosis. 
Thrombocytosis or leukocytosis did not develop in 19 patients venesected during follow-up.  
 
3. Transient erythrocytosis (n=20). Raised Hb/Hct values were non-sustained (hence, transient). Venesections (<3) were 
carried out during the first few months of follow-up in 5 patients but could be terminated with no rebound 
erythrocytosis. In 2 patients RCM confirmed relative erythrocytosis. At diagnosis 4 patients had transient leukocytosis 
and 1 patient had transient thrombocytosis. 
 
4. Secondary erythrocytosis (n=8). One patient had cardiac cyanotic disease. Two patients were referred for JAK2 
analysis after the respiratory physicians had ruled out lung disease, yet after a few years of follow-up early cor 
pulmonale became evident. Three patients were judged to have congenital secondary polycythemia – one with high 
oxygen affinity hemoglobin and two young patients with suspected mutations in the oxygen sensing pathway. 
Leukocytosis/thrombocytosis was not present at diagnosis or follow-up with venesection in the congenital cases. All 6 
these patients had very high sEPO.  The remaining 2 patients with subnormal sEPO values presented with a new cancer 
– cervix carcinoma and nasal neuroblastoma – in both cases erythrocytosis resolved after tumor resection so was clearly 
associated with the tumor. 
 
5. Iatrogenic erythrocytosis (n=9). Five patients underwent splenectomies for diverse reasons (e.g. traumatic, ITP, 
spherocytosis) and 4 patients received androgen replacement therapy (e.g. post total orchidectomy, hypogonadism, 
macroprolactinoma and gender reassignment).  
 
Within the erythrocytosis group, we also described malignancies associated with MPN, as well as whether patients had 
splenomegaly at diagnosis and noted the presence of a raised white cell count or thrombocytosis at initial diagnosis and the 
effects on the counts following venesection.  
 
Malignancies diagnosed at or within 6 months of MPN evaluation: In 2 patients with secondary erythrocytosis a malignancy 
was resected at diagnosis.  No malignancies in IE and transient erythrocytosis; 7 new malignancies in 51 PV patients (14%). 
Splenomegaly at diagnosis: Recorded in 23/51 (45%) PV patients and in 1 patient with IE. 




Table 1. The five subgroups of patients investigated for erythrocytosis (n=139): Distribution of serum Erythropoietin 
level (sEPO); Hb/Hct level according to the WHO and BCSH guidelines; Red Cell Mass (RCM); thrombosis at diagnosis 
and smoking status 
 
* Threshold values for absolute increase in erythrocytosis as set for Hb and Hct by the 2008 WHO and the BSCH 
respectively(McMullin, et al 2005, Vardiman, et al 2009).  
** A1 criterion used in BCSH algorithm for diagnosing JAK2 negative PV(McMullin, et al 2005, McMullin, et al 2007) 
*** There was no significant difference in the proportion of thrombosis between PV and IE (35% in PV vs 34% in IE) (p=0.92).  
† There was no significant difference in the proportion of smokers between PV and IE (63% in PV versus 80% in IE) (p=0.07).  










Idiopathic erythrocytosis  









n= 9 Apparent 
erythrocytosis 
based on RCM 
n=23 
RCM either 
not evaluated  
n= 17 or 
high n=4 
sEPO level       
       Low (<2.6) 71% (6/21) 5% (1/20) 38% (8/21)  25% (2/8)  
       Normal (2.6 – 18.5) 29% (15/21) 80% (16/20) 43% (9/21) 83% (10/12)  50% (2/4) 




      
Hb/Hct consistent 
with increased red 
cell mass* 
100% (51/51) 100% (23/23) 100% (21/21) 64% (14/22) 100% (8/8) 33% (3/9) 
Hct >60 in males, 
>56 in females ** 
39% (20/51) 57% (13/23) 76% (16/21) 32% (7/22) 100% (8/8) 33% (3/9) 
RCM not raised  
(relative 
erythrocytosis) 








35% (18/51) 26% (6/23) 43% (9/21) 36% (8/22) 0% (0/8) 0% (0/9) 
Smokers † 
 
63% (32/51) 78% (18/23) 81% (17/21) 81% (13/16) 50% (4/8) 100% (4/4) 
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Patients Investigated For Leuco- or Thrombocytosis or for Splenomegaly: n=103 
In patients who primarily presented with cytoses other than erythrocytosis or with splenomegaly, our observations were as 
follows. In addition, we noted the prevalence of thrombosis and their smoking histories in this group.  
 
 
Sixty-nine of these patients were proven with an MPN (whether JAK2 positive or negative), 15 patients had a myeloid 
malignancy and 19 patients were systemically ill and had other explanations for the cytoses. 
1. Within the MPN proved group: 
ET was diagnosed in 41 cases, with JAK2 positive in 17 (42%). Twenty-eight PMF cases were identified, of whom 16 
(57%) JAK2 mutated.  
2. Within the myeloid malignancy group:  
In 15 cases the JAK2 analysis was done in the presence of other known myeloid disorders (aplastic anaemia n=2, CML 
n=4, myelodysplastic-myeloproliferative neoplasms n=5, acute myeloid leukaemia n=4) to explore fibrotic or 
proliferative features. The JAK2 mutation was detected in the 2 patients (13%) diagnosed with MDS/MPN with ring 
sideroblasts and thrombocytosis (MDS/MPN-RS-T)(Arber, et al 2016).  
3. Nineteen systemically ill patients who had cytoses were investigated and none were JAK2 mutated – deemed reactive 
because cytoses were explained by the clinical syndromes (figure 1). 
 
Thrombosis prevalence and smoking history at diagnosis: No thromboses recorded in PMF patients or in the 19 patients with 
reactive cytoses. Thromboses were recorded in 42% of ET (see figure 1). JAK2 was not significantly associated with 
thrombosis in ET (p=0.7). There were 24 smokers (59%) among ET patients and 16 (57%) among PMF patients. 
Malignancies diagnosed at or within 6 months of MPN evaluation: One ET patient (2%), 2 PMF patients (7%) and 7 patients 
with reactive cytoses (41%) had newly diagnosed malignancies. 
Splenomegaly at diagnosis: Spleen clinically or radiologically enlarged in 5 ET patients. All PMF patients had splenomegaly. 
Splenic mass present in one patient with reactive cytosis. 










































MPN - Myeloproliferative Neoplasms  | ET - Essential Thrombocytosis  |  PMF - Primary Myelofibrosis
± Thrombocytosis / ± Leukocytosis / ± Splenomegaly




Patients Investigated Solely For Thrombotic Events: n=37 
In this group of patients with thromboses, the JAK2 mutation was requested in the absence of any form of cytosis, whether 
it be erythro-, thrombo- or leukocytosis. We looked at the presumed reasoning behind the requesting of a JAK2 in this 




1. In 20 patients (stroke n=5; VTE n=15) the prompt for JAK2 testing was a thrombotic event, unaccompanied by 
cytosis or splenomegaly.  
2. In 17 patients without cytoses investigation was performed for intra-abdominal thrombotic events, of whom 12 
with proven splanchnic vein thrombosis: (Budd-Chiari syndrome n=6, portal vein thrombosis n=4, inferior vena cava 
thrombosis n=2)  
3. Five patients had no thrombotic event, yet were investigated for possible thrombosis in the diagnostic work-up of 
liver cirrhosis.  
 
Overall Occurrence of Thrombotic Events in All Patients:  
Figure 1 gives a schematic representation of thrombotic events as they occurred in all subgroups. Apart from the 37 patients 
solely investigated for thrombosis, there were thrombotic events in 14/138 patients investigated for erythrocytosis (table 
1), and in 17 patients (with ET) of 103 patients investigated for cytoses. JAK2 positive splanchnic vein thrombosis were 
exclusively found in the cytoses groups: ET (n=2; PV (n=1). Patients with splanchnic vein thrombosis investigated in the 
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A myeloproliferative neoplasm could be detected in 43% of the study population investigated with JAK2 mutation analysis. 
The distribution of the JAK2 mutation in the PV (100%), ET (42%) and PMF (57%) groups was in the region of previously 
reported values.(Kralovics, et al 2005, Tefferi and Barbui 2015) In the small group of patients with other myeloid disorders, 
the JAK2 mutation was found in 13%, namely two patients with MDS/MPN-RS-T.  
 
Using bone marrow histology in conjunction with the WHO diagnostic criteria, it was not difficult to distinguish ET and PMF 
patients from those with non-clonal reactive and inflammatory cytoses. PMF was perfectly correlated with splenomegaly, 
but the same could not be said of ET cases. Therefore, absence of splenomegaly was not a good indicator of reactive cytoses. 
Moreover, malignancies occurred as frequently at diagnosis among patients with clonal cytoses than with non-clonal 
cytoses. Nothing in our analysis suggested that the baseline clinical scenario of ET and PMF patients could be easily 
distinguished from that of non-clonal cytoses cases. Given the low numbers of non-clonal cases tested over a seven-year 
period in our institution, it is clear that the JAK2 mutation analysis was not indiscriminately employed to explore reactive 
thrombocytosis and leukocytosis. 
 
In cases investigated for erythrocytosis, we expected to find some clinical scenarios that should have directed the clinician 
away from the JAK2 test. Indeed, in a few patients the erythrocytosis was clearly the result of a medical intervention. In a 
cost-restrained environment JAK2 testing in these individuals may better be avoided. The fact that erythrocytosis post-
splenectomy is due to redistribution of blood volume was beautifully illustrated in the normal RCM recorded in these 
patients. The link between androgen replacement therapy and a rising hb/hct should also be well known, but it is intriguing 
that RCM study in these individuals revealed spurious erythrocytosis, suggesting androgens may induce a reduced plasma 
volume rather than raised red cell mass(Dickerman, et al 1999, Messinezy and Pearson 1993, Spivak and Silver 2008). 
 
In a minority (14%) of cases, erythrocytosis was not sustained beyond the initial episode and JAK2 mutation analyses were 
consistently negative. Also in these cases the JAK2 mutation analysis may have been requested prematurely and might 
better have been re-considered if erythrocytosis persisted at subsequent follow-up. 
 
There was only one secondary erythrocytosis case – with congenital cardiac cyanosis – where JAK2 testing was clearly 
inappropriate. Ruling out the other patients with secondary erythrocytosis was only possible with the clarity afforded by 
retrospective analysis and in these cases JAK2 testing was essential. All these secondary cases had high sEPO. In contrast, in 
two patients with JAK2 negative erythrocytosis and underlying malignancy, extremely low sEPO levels erroneously pointed 
towards MPN instead of a secondary cause. After resection of tumors in both patients the erythrocytosis – presumably 
driven by an EPO-like substance - resolved completely. This was an unanticipated finding as tumor-related erythrocytosis is 
supposed to be caused by high EPO levels.(Samyn, et al 2004) We were unable to find similar cases in the literature.   
 
JAK2 mutation analysis made it possible to unequivocally diagnose PV in 37% of erythrocytosis cases. Even in PV cases with 
thrombocytosis, we had no difficulty distinguishing PV from ET – a hb/hct that was not in the normal range for our 
laboratory consigned a patient to PV as opposed to ET. This dispensed with the spectre of ‘masked polycythemia vera’ and 
accords with the lower hb/hct threshold in JAK2 positive PV that is now suggested in the revised WHO classification(Arber, 
et al 2016, Barbui, et al 2014b, Barbui, et al 2015)  
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In JAK2 negative erythrocytosis cases with low sEPO, we investigated if low sEPO was associated with true clonal PV cases.  
However, in none of these cases the BME findings were consistent with MPN. Therefore, we could not confirm even a single 
JAK2 negative PV in our series. In agreement with others, we found low sEPO to have no added diagnostic value(Ancochea, 
et al 2014). Diagnostic accuracy in our patients was in accordance with the literature with a low sEPO in only 71% of JAK2 
positive PV cases(Ancochea, et al 2014).  
 
We expected the remaining third of erythrocytosis cases without clear primary or secondary causes to be a diagnostic 
challenge. British and Italian investigators have done the bulk of work trying to make sense of idiopathic erythrocytosis 
(IE)(McMullin 2009, Randi, et al 2016). By definition patients in their registries have an absolute erythrocytosis of idiopathic 
origin, manifested either by a RCM of 125%, or a raised hct above 52 in males and 48 in females. The 44 patients classified 
as IE all had hb/hct values consistent with an absolute increase in red cell mass according to the WHO and BCSH criteria 
(see Table 1). By definition FBC findings alone are sufficient to classify patients with IE (and therefore absolute 
erythrocytosis), however, in the majority (23/27) of our IE patients, RCM revealed an apparent and not an absolute 
erythrocytosis(Johansson, et al 2005, McMullin 2012). No further clarification was gained from sEPO, as patients with IE 
have variable low and high levels unrelated to RCM, as was also confirmed in our cohort(McMullin 2012). 
 
Thus, with few exceptions, an apparent increase in RCM was associated with IE patients. And without exception, an absolute 
increase in RCM was observed in JAK2 positive PV patients. This suggests an innate difference in the actual red cell mass 
between clonal and non-clonal erythropoiesis, regardless of the appearance on peripheral blood. In spite of the similar 
laboratory indices, PV patients are more polycythaemic than IE patients by this measure. Note furthermore that the higher 
BCSH A1 criterium for absolute erythrocytosis (hct >60 in males and >56 in females) was present at diagnosis in only 41% 
of PV and in 44% of IE patients. This percentage is at once much lower than expected for patients with supposed absolute 
erythrocytosis, as well as startlingly similar for two patient groups with completely disparate RCM results. Expert opinion 
maintains that a hct >60, is always correlated with an absolute increase and needs no confirmation with RCM to prove 
absolute erythrocytosis(McMullin 2012). Our results do not confirm this, and on the contrary indicate that RCM is a more 
stringent measurement of raised whole body red cell volume and is more closely aligned with clonal erythropoiesis than 
hb/hct levels.  
 
Another good indicator of the lack of clonality underlying IE, is that, consistent with the findings of Randi et al., not a single 
one of our IE patients developed thrombocytosis following repeated venesection(Randi, et al 2016). This in contrast to the 
majority of JAK2 positive PV cases in our series needing cytoreductive therapy for thrombocytosis in addition to 
venesection. Evidence is lacking that IE patients should be managed in the same way as PV patients but venesection to keep 
the hematocrit at least below 50% is widely practised(Randi, et al 2016). Even through questions of etiology and 
management remain, these patients should be clearly labelled ‘idiopathic erythrocytosis’ so that they can be expertly 
followed and studied for as yet obscure clonal or non-clonal mechanisms of disease.  
 
Based on an empiric impression of the high incidence of smoking, it was at first tempting to explain away idiopathic 
erythrocytosis as ‘smoker’s polycythemia’. The latter remains a poorly delineated concept where the significance of a raised 
carboxyhemoglobin or raised red cell mass and the overlap with early chronic lung disease is difficult to define in the clinical 
setting. However, the similarly high prevalence of smoking in both our PV and IE population, did not point to an additional 
contribution of smoking to idiopathic erythrocytosis. Indeed, the prevalence of lifestyle (smoking) and metabolic 
(thrombosis) determinants between clonal and non-clonal erythrocytosis were strikingly similar in our analysis (Table 1).  
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Thrombosis and smoking were equally prevalent at diagnosis in JAK2 mutated vs unmutated ET, and thrombosis at 42%, 
was higher than the 14% incidence in a recent analysis from the Mayo clinic(Haider, et al 2016). Perhaps in our population 
this is related to poor access to health care resulting in sustained thrombocytosis with late diagnoses and more thrombotic 
events. In our patient population with PV, thrombosis was seen in 29%, not dissimilar to the recently reported 21% 
thrombosis at diagnosis in 1545 PV patients(Barbui, et al 2014a). Not a single patient presenting with thrombosis without 
cytoses tested positive for MPN. Cytoses at diagnosis was also a hallmark of the 3 MPN patients with splanchnic vein 
thrombosis in our series, although splanchnic vein thrombosis cases with masked MPN have been described in the literature. 
Our results confirm that, with the possible exclusion of splanchnic vein thrombosis, the JAK2 mutation analysis should not 
be requested in patients with thrombosis without cytoses(Yonal, et al 2012). It is noteworthy that in our cohort, fewer 
patients with splanchnic thromboses were proven to have a myeloproliferative neoplasm, than comparatively described in 
the literature. 
 
Chronic inflammation and metabolic dysregulation have been shown to influence pathogenesis of MPN(Lindholm Sorensen 
and Hasselbalch 2015, Sorensen and Hasselbalch 2016). Our limited analysis, however, show the features of smoking and 
thrombosis to be equally present in clonal and non-clonal cytoses. This is a novel finding and, in future we aim to further 
explore lifestyle and cardiovascular risk factors in patients investigated for MPN. 
 
We conclude that the JAK2 mutation used in conjunction with the BCSH and 2008 WHO algorithms was an excellent 
clinical tool for differentiating between true clonal myeloproliferation and reactive cytoses. Our analysis confirms that the 
lower hb/hct thresholds in PV are a logical step in the JAK2 era, as now also formalised in the 2016 WHO algorithm(Arber, 
et al 2016). The WHO guidelines for PV brought a new emphasis on trilineage marrow proliferation to the exclusion of other 
minor criteria and our results confirm that BME is indispensable to differentiate between clonal and non-clonal JAK2 
negative erythrocytosis. RCM, which has become redundant in JAK2 positive PV, remains an important tool to further 
characterise JAK2 negative erythrocytosis(Alvarez-Larran, et al 2012), however, due to limited availability its use is 
restricted.  Our finding regarding the lack of agreement between peripheral blood erythrocytosis and RCM measurements 
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Figure 1. Three Clinical Scenarios Prompting JAK V617F analysis in 279 patients: erythrocytosis; 
thrombocytosis ± leukocytosis ± splenomegaly; and thrombosis without cytoses. Subgroups created 
by application of the JAK2 mutation analysis in conjunction with WHO guidelines in the MPN 
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